Industry vet Miles D. Harrison is the President and Chief Executive Officer of Conexeu Sciences Inc., a pre-commercial biotechnology company. He has also been appointed to the Company’s Board of Directors.
Harrison has served as President and CEO, North America at Galderma and was Co-founder and CEO of Novaestiq Corp. Since 2020, Miles has also served on the Board of Castle Biosciences, Inc.
At Conexeu, he will help advance the company’s first-in-class collagen platform for human and animal health. He intends to focus on scientific validation, strategic partnerships, and a unified brand strategy across wound care, dental, and aesthetics.
“Conexeu represents the next frontier,” says Harrison in a news release. “Our CXU collagen platform is positioned as the foundation for regenerative innovation, patented across multiple markets; we are not following trends; we are building a company that we believe will define the future of restoration and renewal and deliver life-changing solutions and a better quality of life to patients and consumers worldwide.”
“Miles brings a rare combination of proven leadership, commercial discipline, market insight, and deep respect for science,” says Jeff Sharpe, Chairman of the Board of Conexeu Sciences Inc. “He has a long history of building high-performance organizations and creating shareholder value, whilst leading teams that consistently outpace the market. His vision positions Conexeu to shape the future of human and animal regenerative medicine.”
Dr. Claudia Chavez-Munoz, Co-Founder and Chief Science Officer of the Company, adds: “True tissue regeneration means complete structural and functional restoration of native tissue. Our CXU platform represents a next-generation liquid extracellular matrix, which provides a complex and bioactive scaffold that mimics the native extracellular matrix architecture, offering cells the biological signals required for organized healing, not scarring. We are delighted to welcome Miles at this pivotal stage; his proven ability to translate scientific innovation into global commercial success will be instrumental in advancing Conexeu’s mission.”
